- Home
- KZIA vs RVYL Comparison
KZIA vs RVYL Comparison
Compare KZIA & RVYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- RVYL
- Stock Information
- Founded
- KZIA 1994
- RVYL 2007
- Country
- KZIA Australia
- RVYL United States
- Employees
- KZIA N/A
- RVYL N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- RVYL Professional Services
- Sector
- KZIA Health Care
- RVYL Consumer Discretionary
- Exchange
- KZIA Nasdaq
- RVYL Nasdaq
- Market Cap
- KZIA 9.0M
- RVYL 7.3M
- IPO Year
- KZIA 1999
- RVYL N/A
- Fundamental
- Price
- KZIA $8.01
- RVYL $0.28
- Analyst Decision
- KZIA Strong Buy
- RVYL Hold
- Analyst Count
- KZIA 2
- RVYL 1
- Target Price
- KZIA $14.00
- RVYL N/A
- AVG Volume (30 Days)
- KZIA 137.3K
- RVYL 5.6M
- Earning Date
- KZIA 11-14-2025
- RVYL 11-13-2025
- Dividend Yield
- KZIA N/A
- RVYL N/A
- EPS Growth
- KZIA N/A
- RVYL N/A
- EPS
- KZIA N/A
- RVYL N/A
- Revenue
- KZIA $1,549,158.00
- RVYL $48,904,000.00
- Revenue This Year
- KZIA N/A
- RVYL $27.50
- Revenue Next Year
- KZIA $49.25
- RVYL $35.71
- P/E Ratio
- KZIA N/A
- RVYL N/A
- Revenue Growth
- KZIA 248983.08
- RVYL N/A
- 52 Week Low
- KZIA $2.86
- RVYL $0.25
- 52 Week High
- KZIA $39.05
- RVYL $2.35
- Technical
- Relative Strength Index (RSI)
- KZIA 49.51
- RVYL 40.18
- Support Level
- KZIA $7.60
- RVYL $0.27
- Resistance Level
- KZIA $8.88
- RVYL $0.31
- Average True Range (ATR)
- KZIA 0.59
- RVYL 0.02
- MACD
- KZIA 0.05
- RVYL 0.00
- Stochastic Oscillator
- KZIA 35.62
- RVYL 16.80
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.